CAM
AGIO icon

Cormorant Asset Management’s Agios Pharmaceuticals AGIO Stock Holding History

Cormorant Asset Management’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-50,000
Closed -$2.1M – 85
2016
Q2 		$2.1M Buy
+50,000
New +$2.47M 0.3% 59
2014
Q4 		– Sell
-100,000
Closed -$6.13M – 71
2014
Q3 		$6.13M Buy
+100,000
New +$4.31M 1.26% 21

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Cormorant Asset Management's AGIO Position: Q3 2016 in Review

Cormorant Asset Management sold out of Agios Pharmaceuticals (AGIO) in Q3 2016, closing a stake of 50,000 shares — an estimated $2.1M sold.

Cormorant Asset Management first reported a position in AGIO in Q3 2014 and held it in 2 quarters. The position peaked at $6.13M in Q3 2014. 164 funds tracked by Wall St. Rank hold AGIO as of Q3 2016.

  • Cormorant Asset Management reported no remaining Agios Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Cormorant Asset Management sold 50,000 Agios Pharmaceuticals shares in Q3 2016, an estimated $2.1M.
  • Cormorant Asset Management first reported a position in Agios Pharmaceuticals in Q3 2014 and held it in 2 quarters.
  • Cormorant Asset Management's Agios Pharmaceuticals position peaked at $6.13M in Q3 2014.
  • 164 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2016.

Based on Cormorant Asset Management's 13F filing for Q3 2016, filed 14 Nov 2016.